Advanced Clinical Research

West Jordan, Utah 84088-9334

0 studies enrolling now · 66 studies all time

What they study most

Alport Syndrome, Alzheimer Disease, Anthrax, Arthritis, Arthritis, Rheumatoid, Autosomal Dominant Polycystic Kidney, CKD Associated With Type 1 Diabetes, COVID-19 Disease, Celiac Disease, Chikungunya Virus, Chikungunya Virus Infection, Chronic Idiopathic Constipation

Studies at this site

• VELOCITY: An Anthrax Vaccine Clinical Study — Completed
• A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia — Completed
• Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection — Completed
• A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older — Completed
• A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL — Completed
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX — Completed
• A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older — Stopped early
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression — Completed
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants — Completed
• A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) — Completed
• A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) — Completed
• Assessment of KAN-101 in Celiac Disease (ACeD) — Completed
• A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine — Completed
• Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure — Stopped early
• Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults — Completed
• Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men — Completed
• Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults — Completed
• A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease — Paused
• PSD502 in Subjects With Premature Ejaculation — Completed
• Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year. — Completed
• Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults — Completed
• Gan & Lee Insulin Glargine Target Type (2) Evaluating Research — Completed
• A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults — Completed
• Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03 — Stopped early
• Diabetic Gastroparesis Study 05 — Stopped early
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04 — Stopped early
• Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 — Stopped early
• A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study — Stopped early
• Dextromethorphan Pediatric Acute Cough Study — Stopped early
• A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) — Completed
• Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen — Completed
• Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue — Completed
• Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults — Completed
• Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease — Completed
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults — Completed
• Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study — Completed
• A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age — Completed
• Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose — Completed
• Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. — Completed
• Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain — Completed
• A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants — Completed
• A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers — Completed
• The Plecanatide Chronic Idiopathic Constipation (CIC) Study — Completed
• Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin — Stopped early
• A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects — Completed
• A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age — Completed